Medical Device Regulations & Compliance

INDUSTRY PERSPECTIVES

EU MDR: When Products Without An Intended Medical Purpose Meet Medicinal Substances

One major change introduced by the EU MDR compared to the former European directives is the inclusion of products without an intended medical purpose but with similar risk profiles to medical devices, such as dermal fillers.

RFK Jr. Wants Every American Wearing A Wearable. How Can Pharma Build A Business Around It?

The timing is now for pharma to be all-in on using wearables as their new business strategy, says Digital Medicine Society (DiMe) Director of Partnerships Smit Patel, PharmD.

Staying Ahead of Enforcement: Executive Strategies To Prevent FDA Warning Letters

This article focuses on practical strategies for medical device companies to strengthen their quality management systems and develop proactive programs that anticipate issues before they attract FDA action. 

Regulatory Planning In Early Medtech Development Is The Recipe For Success

Historically, many medtech companies have engaged with the FDA in a conservative way, providing only the minimum required to obtain clearance or approval. That mindset is no longer enough. 

WHITE PAPERS & CASE STUDIES

Leverage Apps To Reduce Line Changeover Time From 14 Days To 3

A global biopharma leader modernized its complex equipment changeover process using an innovative platform to achieve faster execution, fewer errors, and greater visibility through digitized, validatable SOPs.

The 5 Ws Of A Human Factors Strategy

A human factors strategy ensures medical products are safe, effective, and compliant by integrating user-focused design early, reducing risks, and optimizing regulatory approval processes.

Selecting The Best Deterministic Method For Your CCIT Project

Container Closure Integrity Testing (CCIT) ensures drug sterility, evolving with regulatory updates like USP <1207>. Deterministic methods are preferred over probabilistic ones to maintain product integrity.

Meeting Annex 1: A Proactive Approach To Regulatory Compliance

It was imperative for a large European CMO that produces multiple biologic drugs to select the right product quality and value for each customer to comply with the August 2023 revision to the EU GMP Annex 1.

LATEST HEADLINES